Drug efficacy studies in the Vκ*-MYC model predict single-agent drug activity in multiple myeloma, with a positive predictive value of 67% (4 of 6) for clinical activity, and a negative predictive value of 86% (6 of 7) for clinical inactivity (16, 18). Here, MYC is linked to plasma cell myeloma.